vTv Therapeutics Inc. Class A Common Stock (VTVT)

Data is currently not available

Quotes

NEWS & ANALYSIS

VTVT VTVT PRESS RELEASES

VTVT Press Releases

Published
Jan 6, 2021

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

Published
Jan 6, 2021
Published
Dec 15, 2020

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes

Published
Dec 15, 2020
Published
Dec 15, 2020

Aditum Bio Announces Formation of Third Company, Anteris Bio

Published
Dec 15, 2020
Published
Dec 15, 2020

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

Published
Dec 15, 2020
Published
Nov 24, 2020

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

Published
Nov 24, 2020
Published
Nov 5, 2020

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

Published
Nov 5, 2020
Published
Nov 4, 2020

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

Published
Nov 4, 2020
Published
Oct 29, 2020

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event

Published
Oct 29, 2020
Published
Sep 23, 2020

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

Published
Sep 23, 2020
Published
Sep 16, 2020

vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting

Published
Sep 16, 2020
Published
Sep 15, 2020

vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors

Published
Sep 15, 2020
Published
Aug 3, 2020

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

Published
Aug 3, 2020
Published
Jul 27, 2020

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

Published
Jul 27, 2020
Published
Jun 13, 2020

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

Published
Jun 13, 2020
Published
May 22, 2020

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

Published
May 22, 2020
Published
May 7, 2020

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

Published
May 7, 2020
Published
Feb 20, 2020

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Published
Feb 20, 2020
Published
Feb 10, 2020

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

Published
Feb 10, 2020
Published
Feb 7, 2020

vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

Published
Feb 7, 2020
Published
Dec 2, 2019

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Published
Dec 2, 2019
Back to VTVT Overview

Related Symbols

AMZN

Data is currently not available
AAPL

Data is currently not available
TSLA

Data is currently not available
INTC

Data is currently not available